Numerous immunoglobulins have been produced on a wide scale utilizing conventional procedures ever since the invention of antibody-production techniques. The generation of antibodies against target antigens for infectious diseases, malignant diseases, autoimmune disorders, and several powerful toxins has expanded thanks to hybridoma technology.
However, these clinical, humanized, or chimeric murine antibodies have several drawbacks and complications. Because of this, new developments in genetic engineering methods and phage display technology have made recombinant antibody production possible.
Such engineered antibodies were developed to facilitate the search for novel therapeutic drugs with improved immunoprotective properties, such as activating immune effector functions, developing successful fusion proteins, ensuring effective tumor and tissue penetration, and creating high-affinity antibodies directed against conserved targets.
Numerous uses for these advanced antibody engineering techniques can be found in immunology, biotechnology, diagnostics, and medicine.
What are Antibodies?
An immune system component known as an antibody is a protein that can bind to an antigen with high specificity. Though these antigens are usually proteins, they can also be sugars, small compounds, or nucleotides.
Because antibodies bind selectively to a single epitope on an antigen, they are effective research tools that enable the identification of a particular protein in an assay while preventing the detection of unrelated proteins.
Thanks to these binding capabilities, antibodies can be utilized in diagnostic procedures like pregnancy testing and treatments like cancer immunotherapy.
The antibody is a Y-shaped protein with a variable section that is exclusive and specific to an individual epitope, and a constant segment shared by all antibodies produced by a species.
Antibody Production
It is helpful to understand how antibodies are made by the immune system while building a custom antibody, even though this article does not focus on the intricate mechanics of the immune response.
When an organism's immune system comes into contact with a foreign molecule (usually a protein) for the first time, specialized cells like dendritic cells and macrophages seize the molecule and break it down to present these antigens to B lymphocytes.
A process known as somatic hypermutation enables B cells to start coding for a new antibody after antigen presentation has occurred. This antibody will have a distinctive antigen-binding site in the variable region that can bind specifically to an epitope from the antigen.
Each B lymphocyte produces a distinct antibody in response to a specific epitope. The B cell starts to release antibodies into the bloodstream once they are encoded with enough specificity for the epitope. These antibodies then selectively bind to the foreign molecule, enabling the immune system to eliminate it.
The critical function of these antibodies can occasionally be to neutralize endotoxins. In other circumstances, such as when dealing with bacterial pathogens, these antibodies bind to surface proteins on the bacteria, alerting the immune system to eliminate the pathogen.
B cells stay in the bloodstream after the foreign material has been removed and are prepared to generate antibodies if the antigen is met again.
The immune system captures the protein, dissects it into individual epitopes, and then sends these epitopes to the B cells so that antibody production specific to those epitopes can start. This is the same process used when generating a bespoke antibody against a protein antigen.
Then, these antibodies can be isolated from the individual B cells that make antibodies against the desired epitope or directly collected from the serum. When an antigen is a full-length protein, several B cells typically produce antibodies against multiple epitopes from various sections of the protein.
Methods of Antibody Production
Different processes are involved in how antibodies are produced, depending on the type of antibody required. Therefore, the following sections describe the procedures for creating monoclonal or polyclonal antibodies.
The Process for Making Monoclonal Antibodies
Monoclonal antibodies only detect one epitope per antigen since they are derived from a single B-cell clone. These B cells become immortal by fusing with myeloma cells to create hybridomas, enabling the long-term production of identical monoclonal antibodies.
Monoclonal antibodies are less likely to cross-react with different proteins than polyclonal antibodies because they precisely recognize a specific epitope on the antigen.
Animals like mice, rabbits, chickens, and rats can all be used to manufacture monoclonal antibodies. Rabbits are often preferred because of their immune systems' capacity to mount a potent response to antigen presentation. Steps in the production of monoclonal antibodies include the following:
Vaccination of Animals
Immunizing the animal with a pure antigen coupled to a carrier protein like KLH is the first step in manufacturing monoclonal antibodies. The investigator subcutaneously injects the antigen complex and adjuvant, and the injection is repeated several times along a predetermined timeline based on antibody titers measured throughout the treatment.
These injections stimulate the B lymphocytes that react to the antigens.
Three days before the cells are harvested, the animal receives one more injection of the antigen; however, this time, the researcher delivers it intravenously. The researcher euthanizes the animal and extracts the spleen as a cell source for fusion with myeloma cells once the antibody achieves a high enough titer.
Fusion and Selection
Myeloma-derived cells and antibody-producing spleen cells can be combined to form hybrids. The resulting hybridoma cell line has limitless growth potential. Before cell fusion, myeloma cells must proliferate, have high viability, and be cultured for one week.
Purification of Antibodies
Monoclonal antibodies must be purified before use. Protein A or Protein G affinity chromatography is the industry standard for the purification of monoclonal antibodies. Because of its efficiency, leading scientists have embraced this technology.
However, alternative, cutting-edge purification techniques, such as size exclusion or antigen-specific affinity chromatography, might be employed for applications requiring higher purity levels.
Quality Assurance
After the purification procedure, monoclonal antibodies are examined using quality control assays. The most popular technique for determining the quality of a monoclonal antibody is the ELISA test.
Production of Polyclonal Antibodies
The immunological response of various B cells produces a heterogeneous mixture of polyclonal antibodies, each of which detects a different epitope on the same antigen.
Polyclonal antibodies are more susceptible to batch-to-batch variability than monoclonal antibodies because they comprise a variety of antibodies that mimic the body's normal immunological response to an antigen.
Antigen Preparation
Preparing the antigen, often using an amino acid sequence obtained from the target, is the first step in producing polyclonal antibodies. When binding with conformational epitopes is required, you must choose unique and immunogenic antigens.
Any antigen impurity may result in the development of antibodies that are more potent against the impurities than the target antigens.
Vaccination of Animals
Specialized adjuvants are used to boost the immune response to generate polyclonal antibodies. One of the adjuvants frequently utilized in research is Freund's adjuvant. The chosen animal (often a rabbit) can receive an intramuscular, subcutaneous, or intradermal injection of the antigen.
Four to eight weeks following the priming vaccination, booster shots are given. The process then continues every two to three weeks. After each booster shot, the animal is bled, and the blood is used to create the serum.
Purification of Antibodies
A helpful way to purify polyclonal antibodies is through affinity purification. Immunoglobulin G (IgG) can be concentrated, and undesirable proteins removed from the serum during the purification process. Antigen-specific affinity purification is used to isolate a polyclonal antibody from antiserum specifically.
Quality Control
After purification, quality control tests are run to ensure the polyclonal antibodies generated are of high quality. SDS-PAGE verifies purity, and spectrophotometry measures concentration using absorbance at 280 nm (A280).
The Quickest Method to Increase Antibody Production
Researchers have created a revolutionary method to produce human antibodies in the lab. This innovative technique could be applied to the creation of novel vaccinations in addition to accelerating the production of antibodies to treat various ailments.
B cells are specialized immune system cells that create antibodies to combat illnesses brought on by pathogens, including bacteria, viruses, or other disease-causing microbes. A specific pathogen-derived antigen, a substance that triggers an immune response in the body, is recognized by a particular B cell.
The B cells rapidly expand after identifying the antigen and transform into plasma cells, which generate huge quantities of antibodies that bind to the antigen to combat the infection.
Treating B Cells with Coated Nanoparticles
The "infection-fighting" procedure has previously been replicated in a laboratory by manufacturing specific antibodies from B cells isolated from patient blood samples. For B cells to start multiplying and turning into plasma cells, they require two signals.
The first signal comes from contacting and recognizing a particular antigen, while the second signal comes from short DNA fragments called CpG oligonucleotides. CpG oligonucleotides stimulate proliferation by activating the TLR9 protein in B cells.
Studies have demonstrated that when patient-derived B cells are treated with CpG oligonucleotides, all of the B cells in the sample are activated, not just those capable of secreting a specific antibody. Researchers induced the production of specific human antibodies by using tiny nanoparticles coated with the necessary antigen and CpG oligonucleotides on patient-derived B cells.
The CpG oligonucleotides only internalize into B cells that detect the specific antigen, which makes the team's innovative technique effective. As a result, only these B cells undergo TLR9 activation, which allows them to multiply and transform into plasma cells that produce antibodies.
Anti-HIV Antibodies from HIV-free Patients
Batista and colleagues have shown that their technique effectively uses bacterial and viral antigens, such as tetanus toxoid, and proteins from several influenza A strains.
Over just a few days, the researchers could manufacture specific antibodies. Some of the produced anti-influenza antibodies could detect different virus strains and neutralize their capacity to infect cells.
The procedure is also independent of the donor's exposure to antigens from illnesses or vaccines. The researchers proved this by producing anti-HIV antibodies from B cells derived from healthy individuals. This novel strategy could aid in quickly producing therapeutic antibodies for treating infectious diseases and perhaps even other illnesses like cancer.
Use of Small Immunogenic Molecules to Stimulate Antibody Generation
Low molecular weight compounds (< 1,000 Da) frequently lack immunogenicity by nature. Therefore, they cannot be utilized directly to stimulate the synthesis of antibodies. In these situations, coupling the small molecule with a larger carrier protein can be used to develop efficient active immunization techniques. The complex, not the hapten by itself, triggers the formation of antibodies.
This phenomenon is known as the anti-hapten response. Thus, haptens only cause an immunological reaction when joined to a carrier macromolecule. Although haptens are a structurally and chemically diverse group, creating hapten conjugates is a chemically complex procedure.
Special attention must be paid to the coupling method and the hapten-to-carrier molar ratio when a hapten is utilized for immunization. These two elements directly affect the strength of the immunological response.
The most frequently used carrier proteins include globulins, albumins, gelatin, casein, and toxoids for tetanus, cholera, or diphtheria. Natural immunogenicity and the availability of sufficient reactive side chains for conjugation with the hapten are the only conditions for a suitable carrier molecule.
Diverse conjugation techniques are also used. For instance, the conjugation may occur spontaneously when the hapten is chemically reactive. However, when natural reactivity is low, haptens can be crosslinked with intermediary molecules like carbodiimides or glutaraldehyde.
Bottomline
In recent decades, antibodies have been created utilizing traditional methods like hybridoma technology, which has had significant therapeutic implications. However, more recent developments in recombinant technology have improved the production of effective immunoglobulins and their fragments.
The creation of high-affinity peptides and proteins, research into protein-protein interactions, receptor binding, and epitope identification are all possible with the help of antibody engineering. This provides quick, affordable, and effective biomedical tools. From cell biology and biotechnology perspectives, various systems employ this powerful technology to address multiple challenges.
Additionally, these methods are utilized to create various kinds of engineered antibodies that can be directed against any target molecule or specific, distinct conserved antigens. Furthermore, this technology helps with infection diagnosis and treatment to enhance human health.
Therapeutic antibodies are one of the pharmacological classes with the most significant growth in the fight against cancer and autoimmune disorders. Biotechnology and pharmaceutical firms typically need to create vast quantities of antibodies repeatedly to explore various functional features and locate the most promising candidates.
Every step of this lengthy process slows down the discovery of new drugs. Many businesses are turning to contract research organizations (CROs) like Biomatik that offer services for drug development, from recombinant antibody services to antibody sequencing services, allowing the production of many antibodies in less time.